Key clinical point: Two first-line treatments for chronic hepatitis B virus may differ in their ability to prevent hepatocellular carcinoma.
Major finding: In a propensity score-adjusted analysis, treatment with tenofovir disoproxil linked with a 64% reduced incidence of hepatocellular carcinoma.
Study details: Review of 29,350 Hong Kong residents treated for chronic hepatitis B infection during 2010-2018.
Disclosures: Dr. Wong has been an adviser to Gilead, and has been a speaker on behalf of Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Furui, Gilead, Janssen, and Roche. Tenofovir disoproxil fumarate (Viread) is marketed by Gilead, and entecavir (Baraclude) is marketed by Bristol-Myers Squibb.
Wong GL et al. J Hepatol. 2019 April;70:e128.